Main menu
Common skin conditions
NEWS
Join DermNet PRO
Read more
Quick links
Last Reviewed: October, 2026
Author: Dr Gabrielle McLean, Dermatology registrar, Dermatology, Auckland City Hospital,
New Zealand (2025)
Peer reviewed by: Dr Zsófia Hermann, Paediatric registrar, Tauranga Hospital, New Zealand (2026)
Previous contributors: Vanessa Ngan, Staff Writer (2003). Jane Widdowson, EB Clinical Nurse Specialist, NZ (2016).
Reviewing dermatologist: Dr Ian Coulson
Edited by the DermNet content department.
Introduction
Demographics
Causes
Clinical features
Complications
Diagnosis
Severity assessment
Differential diagnosis
Treatment
Prevention
Outcome
Treatment
Epidermolysis bullosa (EB) is a group of inherited diseases that are characterised by skin fragility and blistering lesions on the skin and mucous membranes.
The blistering lesions may occur anywhere on the body but most commonly appear at sites of friction and minor trauma such as the feet and hands. In some subtypes, blisters may also occur on internal organs, such as the oesophagus, stomach and respiratory tract, without any apparent friction.

Recessive dystrophic epidermolysis bullosa in a neonate

Epidermolysis bullosa

Epidermolysis bullosa simplex on the palms

Dystrophic epidermolysis bullosa showing erosions, blisters, and nail dystrophy

Severe dystrophic epidermolysis bullosa showing blisters, erosions, and scars

Epidermolysis bullosa showing herpetiform blisters on the lips and face

Severe dystrophic epidermolysis bullosa in a neonate

Dystrophic epidermolysis bullosa on the hand in a neonate

Dystrophic epidermolysis bullosa on a neonate’s face
EB should be distinguished from common friction blisters, and from epidermolysis bullosa acquisita (EBA), which is an acquired blistering autoimmune disease that is not inherited and often does not develop until adult life.
The EB conditions result from genetic defects of molecules in the skin concerned with adhesion. Loss of adhesion results in blister formation. EB is classified into four major classical subtypes, each distinguished by the level of tissue separation within or beneath the basement membrane zone (BMZ):
EB type |
The site of blister formation within skin |
|---|---|
Epidermis or uppermost layer of skin cells (keratinocytes) |
|
Lamina lucida within the BMZ |
|
Lamina densa and upper dermis |
|
Mixed cleavage pattern |
Within each of these types of EB, there are various subtypes. Varying degrees of severity that range from mild to severe are found with each EB type. The 2020 International consensus on the diagnosis and classification of EB notes that while other skin fragility conditions, eg, peeling skin disorders, erosive disorders, hyperkeratotic disorders, and connective tissue disorders with skin fragility are classified as separate categories; these ‘EB‐related’ disorders should be considered under the EB umbrella in terms of medical and socioeconomic provision of care.
Epidermolysis bullosa is a rare, inherited disease with reported prevalence varying between populations. Males and females are equally affected. EB usually presents at birth or shortly after, although mild forms may not be diagnosed until childhood or adulthood.
Epidermolysis bullosa is a genetic disorder caused by pathogenic variants in genes encoding proteins involved in epidermal adhesion and skin integrity. Inheritance may be autosomal dominant or autosomal recessive depending on the subtype.
Pathogenic variants in multiple genes encoding proteins involved in epidermal adhesion and skin integrity cause the different EB subtypes.
Epidermolysis bullosa has varying clinical features depending on the specific subtype.
Epidermolysis bullosa simplex (EBS)
Junctional epidermolysis bullosa (JEB)
Dystrophic epidermolysis bullosa (DEB)
There are many other subtypes of EB. The presentation and severity of EB is affected by the specific genetic changes and can at times be difficult to classify.
Epidermolysis bullosa may vary in its presentation according to skin phototype. In darkly pigmented skin, erythema associated with blistering and inflammation may be less apparent, while post-inflammatory hyperpigmentation may be more prominent. Clinicians should therefore assess for blistering, erosions, scarring and pigmentary changes rather than relying on erythema alone.
Epidermolysis bullosa has various complications depending on the subtype. Specific subtypes of EB associated with severe phenotypes can even involve other organ systems. Some examples include:
Epidermolysis bullosa is diagnosed based on clinical features and laboratory testing. Immunofluorescence mapping and molecular genetic testing are used to confirm the diagnosis and subtype. In neonates, immunofluorescence mapping can provide a rapid diagnosis, with genetic testing performed in parallel.
The precise subtype can improve prognostication, and enable genetic counselling, prenatal diagnosis, inclusion in clinical trials and precision medicine. A referral to a dermatologist will be required.
The severity of EB can be assessed using the following scoring systems:
There is no definitive cure for most forms of EB. Ongoing research into gene and cell therapies aims to improve quality of life and disease outcomes.
Treatment is primarily symptomatic. Theprimary aim is to protect the skin and stop blister formation, promote healing, and prevent complications. Because EB can affect so many different parts of the body, a team of medical specialists is usually required for overall care.
Clinical practice guidelines are available on the DEBRA (Dystrophic Epidermolysis Bullosa Research Association) international website including those on oral Health care, wound Care, pain management, and cancer management.
Further support and information from both health care professionals and those affected by EB:
Early interventions for any significant extracutaneous complications include:
Epidermolysis bullosa is an inherited condition which is the result of pathogenic genetic variants, therefore there is no way to prevent its development. However, trauma-minimisation and appropriate wound care can help prevent or reduce blistering and its complications.
Prenatal diagnosis by skin biopsy or chorionic villus biopsy can be offered to families where the precise molecular defect is known from previously affected individuals in the family. Embryo selection and implantation has the possibility of selecting a foetus that is unaffected by a severe EB variant.
Epidermolysis bullosa should be correctly diagnosed and subclassified so that the expected severity and prognosis of the disease can be determined. Mild forms of EB can improve with age, whereas severe forms are associated with early mortality.